Immunocore Holdings PLC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Immunocore Holdings plc announced significant revenue growth for 2025, driven by its lead product KIMMTRAK, while also reducing its net loss, signaling progress in its commercialization and pipeline development.
NASDAQ
10-K: Immunocore Holdings plc Reports Annual Results for 2024, Highlights Strategic Priorities for 2025
Immunocore Holdings plc announces its 2024 financial results, highlighting KIMMTRAK's commercial progress and outlining strategic priorities for 2025, including expanding its melanoma franchise and advancing its clinical portfolio.
NASDAQ
Immunocore Holdings plc, a commercial-stage biotechnology company, released its full year 2023 results, showcasing revenue growth from KIMMTRAK and advancements in its ImmTAX platform.